New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
09:14 EDTBKS, CYTR, ORCL, FIO, MON, VVUS, LQDT, PLUG, LMCA, CACIOn The Fly: Pre-market Movers
HIGHER: Plug Power (PLUG), up 3% after agreeing to acquire hydrogen fuel cell stack technology developer ReliOn... Fusion-io (FIO), up 2% after announcing a collaboration with Oracle (ORCL) on the development of flash-aware interfaces for MySQL... Monsanto (MON), up 1.5% following upgrades to Overweight at JPMorgan... CytRx (CYTR), up 9.7% after announcing data from a trial that it said supports the current evaluation of aldoxorubicin as a treatment for patients with GBM tumors. LOWER: Liquidity Services (LQDT), down 13% after confirming it withdrew from live auction bidding for the DoD rolling stock contract, shares downgraded to Neutral at RW Baird... Barnes & Noble (BKS), down 9% after Liberty Media (LMCA) agreed to reduce its stake in B&N... VIVUS (VVUS), down 5% following downgrade to Underweight at Piper Jaffray... CACI International (CACI), down 8.7% after cutting its fiscal 2014 earnings and sales outlook, citing reduced government spending and delays in award activity.
News For BKS;LMCA;PLUG;LQDT;VVUS;MON;FIO;ORCL;CYTR;CACI From The Last 14 Days
Check below for free stories on BKS;LMCA;PLUG;LQDT;VVUS;MON;FIO;ORCL;CYTR;CACI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
September 11, 2014
10:30 EDTORCLUBS sees increasing likelihood of change at EMC
UBS calls the New York Post "surprisingly accurate on M&A" after the paper reported that EMC (EMC) is considering the sale of its stake in VMware (VMW). The firm believes the likelihood for change at the company is rising. In addition, UBS says the industry should consolidate, and it views EMC as a potential target. UBS thinks Cisco (CSCO), Oracle (ORCL) and HP (HPQ) might be interested parties in owning part or all of EMC. The firm believes an HP, EMC merger would make sense. UBS has a Buy rating on EMC with a $33 price target.
08:01 EDTVVUSOrexigen Contrave could have stronger launch than peers, says Wells Fargo
After the FDA approved Orexigen's (OREX) Contrave as a treatment option for chronic weight management, Wells Fargo does not believe the label included any significant surprises. The firm thinks multiple factors increase the chances that Contrave's launch will be stronger than two other weight loss drugs that were launched in recent years by VIVUS and Arena Pharmaceuticals (ARNA). The firm keeps an Outperform rating on Orexigen.
September 10, 2014
11:29 EDTMONMonsanto's Intacta remains on track, says Credit Suisse
Credit Suisse said Monsanto Intacta demand remains strong and check's indicate it is fully on track to meet the high end of its 10m-12M acre guidance for Brasil.
11:22 EDTBKSOptions with decreasing implied volatility
Subscribe for More Information
11:20 EDTMONMonsanto: Intacta demand 'in line,' pre-pays above expectation, Bloomberg says
Subscribe for More Information
10:51 EDTORCLOracle September volatility elevated into Q1 and outlook
Oracle September call option implied volatility is at 28, October is at 18, December is at 19; compared to its 26-week average of 23 according to Track Data suggesting large near term price movement into the expected release of Q1 results after the close on September 18.
10:43 EDTMONMonsanto shares defended at JPMorgan
Subscribe for More Information
09:39 EDTMONMonsanto view downgraded to Negative from Mixed at OTR Global
Subscribe for More Information
07:23 EDTORCLOracle coverage assumed with a Neutral at MKM Partners
Subscribe for More Information
September 9, 2014
12:46 EDTVVUSNovo Nordisk weight loss drug helped people get thinner, Bloomberg reports
Subscribe for More Information
12:02 EDTBKSOptions with decreasing implied volatility
Options with decreasing implied volatility: KERX CIEN FNSR PAY BKS PVH NAV BYI FTR JOY
10:29 EDTBKSBarnes & Noble says third parties see value in NOOK assets
Subscribe for More Information
10:18 EDTBKSBarnes & Noble says won't launch new bn.com in time for holiday season
Says "extremely happy" with Retail's Q1 performance, sees moderation of physical booksales decline. Says sees sales lift due to dispute between Amazon (AMZN) and Hachette. Regarding the launch of bn.com says making progress on development, but completion taking longer than expected. The company plans to launch the new site later this FY, but not in time for holiday season. Comments made on the Q1 earnings conference call.
08:37 EDTBKSBarnes & Noble's NOOK launched first co-branded tablet with Samsung
Subscribe for More Information
08:33 EDTBKSBarnes & Noble sees FY15 college SSS to decline low-single digits
For FY15 the company continues to expect both Retail comparable bookstore sales and Retail Core comparable bookstore sales to decline in the low-single digits. College comparable store sales are also expected to decline in the low-single digits. The company expects full fiscal year EBITDA losses in the NOOK segment to decline versus the prior year.
08:32 EDTBKSBarnes & Noble says making progress on separation of Retail and NOOK Media
Subscribe for More Information
08:32 EDTBKSBarnes & Noble reports Q1 EPS (56c), consensus (63c)
Reports Q1 revenue $1.2B, consensus $1.26B. “Core” comparable bookstore sales, which exclude sales of NOOK products, decreased 0.4% for the quarter. Comparable College store sales decreased 2.0% for the quarter, primarily impacted by the timing of the start of the back-to-school rush season as compared to last year. Comparable College store sales reflect the retail selling price of new or used textbooks when rented, rather than solely the rental fees received and amortized over the rental period. The NOOK segment had revenues of $70 million for the quarter, decreasing 54.3% from a year ago.
07:17 EDTORCLThe Wireless Association to hold a conference
Subscribe for More Information
06:29 EDTBKSBarnes & Noble results likely to highlight retail business strength, WSJ says
Subscribe for More Information
06:06 EDTCYTRCytRx begins enrollment for Phase 1b clinical trial of aldoxorubicin
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use